GlobeNewswire Inc | Mar 16, 2021 04:05PM EDT

March 16, 2021

MENLO PARK, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today thatthe company will release its fourth quarter 2020 financial results after the market closes on Tuesday, March 30, 2021. Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the companys business.

Details for the Conference Call and Slide Presentation:

Date: March 30, 2021Time: 5:00 p.m. ET (2:00 p.m. PT)

Conference Audio

-- Dial-in U.S. and Canada: (877) 451-6152 -- Dial-in International: (201) 389-0879 -- Conference ID No.: 13717040

Slide Presentation

-- Go to www.webex.com, click on the Join a Meeting button and enter meeting number 145 355 3814 and password CWBR, or -- Go to www.cohbar.com and click on Q4 2020 Shareholder Presentation at the top of homepage.

For individuals participating in the Investor Call and Slide Presentation, please call into the conference audio and log into Webex approximately 10 minutes prior to its start.

An audio replay of the call will be available beginning at 8:00 p.m. Eastern Time on March 30, 2021, through 11:59 p.m. Eastern Time on April 20, 2021. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 13717040. The audio recording along with the slide presentation will also be available at www.cohbar.com during the same period.

About CohBar

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBars founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome,some of whichhave been shown tohave the potential to regulatekey processes inmultiplesystems andorgans in the body. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBars efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseasesassociated with the underlying impact of mitochondrial dysfunction. The companys lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity. In addition, CohBarhas four preclinical programs: CB5138 Analogs for fibrotic diseases,CB5064 Analogs for COVID-19 associated ARDS, CB5046 Analogs for CXCR4-related cancer and orphan diseases, and MBT3 Analogs for cancer immunotherapy.

For additional company information, please visit www.cohbar.com.

Contacts:

Jordyn TaraziDirector of Investor RelationsCohBar, Inc.(650) 445-4441Jordyn.tarazi@cohbar.com